Table 6 Competing risk regression analyses for cancer survival among Aboriginal and matched non- Indigenous cohorts by concurrent treatment type
| Â | Model 7 - any treatment mode | ||
|---|---|---|---|
Subhazard Risk Ratio | 95% CI | p > |z| | |
Aboriginal x geographic remoteness non- Indigenous | |||
 not Remote | 0.70 | 0.58–0.83 | <0.001 |
 Remote | 0.77 | 0.37–1.61 | 0.49 |
Aboriginal | |||
 not Remote | 1.00 | Reference |  |
 Remote | 1.53 | 1.02–2.28 | 0.04 |
Comorbidity score (Elixhauser) | |||
 0–3 | 1.00 | Reference |  |
 4+ | 1.72 | 1.16–2.54 | <0.01 |
Stage x treatment modality | |||
 Any stage with surgery | 0.56 | 0.36–0.86 | <0.01 |
 Local stage without surgery | 1.00 | Reference |  |
 Not local stage without surgery | 1.12 | 0.66–1.89 | 0.68 |
 Local stage with/without systemic therapy | 0.50 | 0.33–0.76 | <0.001 |
 Not local stage with systemic therapy | 1.00 | Reference |  |
 Not local stage without systemic therapy | 1.55 | 1.15–2.08 | 0.004 |
 Local stage without radiotherapy | 0.39 | 0.22–0.67 | <0.001 |
 Not local stage without radiotherapy | 1.00 | Reference |  |
 Any stage with radiotherapy | 1.11 | 0.82–1.50 | 0.51 |
BIC | 650.2 | Â | Â |